Lipid-lowering drugs

Lipid-lowering drugs

Accumulating evidences in recent major clinical studies have shown the importance of anti-hyperlipidemic treatment in preventing atherosclerotic cardiovascular diseases. Lipid-lowering drugs can be divided into HMG-CoA reductase inhibitors (statins), bile-acid sequestrants (resins), nicotinic acid,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Folia Pharmacologica Japonica 2001, Vol.118(6), pp.389-395
Hauptverfasser: HIRAKAWA, Yoji, SHIMOKAWA, Hiroaki
Format: Artikel
Sprache:jpn
Schlagworte:
Benzamides
Cyclohexanes
Dioxanes
Drug Design
Enzyme Inhibitors
F-1394
Fluorobenzenes
Gemfibrozil
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypolipidemic Agents - classification
Japan
NO-1886
Organophosphorus Compounds
pitavastatin
Pyrimidines
Quinolines
rosuvastatin
Rosuvastatin Calcium
Sterol O-Acyltransferase - antagonists & inhibitors
Sulfonamides
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Accumulating evidences in recent major clinical studies have shown the importance of anti-hyperlipidemic treatment in preventing atherosclerotic cardiovascular diseases. Lipid-lowering drugs can be divided into HMG-CoA reductase inhibitors (statins), bile-acid sequestrants (resins), nicotinic acid, fibrates and probucol. Among them, statins had revolutionary impact on the treatment of hyperlipidemia since pravastatin, which was developed in Japan, was launched in 1989. Several lipid-lowering drugs are now under development in Japan, including pitavastatin, rosuvastatin, F-1394 (ACAT inhibitor), CS-505 (ACAT inhibitor) and NO-1886 (LPL activator). In this review, characteristics of these new lipid-lowering drugs will be discussed.
ISSN:0015-5691
1347-8397
DOI:10.1254/fpj.118.389